You are here

  • Home
  • Archive
  • Volume 107, Issue 3
  • Use of peripheral vasoactive drug infusions during the critical care transport of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Use of peripheral vasoactive drug infusions during the critical care transport of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection
  1. Mithila D'Souza,
  2. Susannah Pye,
  3. Elise Randle,
  4. Padmanabhan Ramnarayan,
  5. Andrew J Jones
  1. Children's Acute Transport Service, Great Ormond Street Hospital for Children, London, UK
  1. Correspondence to Dr Mithila D'Souza; mithila.d'souza{at}gosh.nhs.uk

https://doi.org/10.1136/archdischild-2021-322674

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS)—also known as multisystem inflammatory syndrome in children (MIS-C)—frequently presents with signs of shock and is treated with vasoactive drugs.1 Infusing vasoactive drugs via a peripheral venous line (PVL) has utility in the acute setting but carries the risk of extravasation.2

    We report on a cohort of children with PIMS-TS/MIS-C who received epinephrine and/or norepinephrine infusions via a PVL during transport to a paediatric intensive care unit (PICU) between 1 August 2020 and 28 February 2021. The diagnosis of PIMS-TS/MIS-C was made by a multidisciplinary team. The initial choice of vasoactive drug(s) and route of administration was decided by the transport consultant and the referring team, with reference to service guidelines.3 During the study period epinephrine and norepinephrine for peripheral administration were made as 0.3 mg/kg in 50 mL diluent for children up to and including 13 kg, and 4 mg in 50 mL for children …

    View Full Text

    Footnotes

    • Contributors AJ and MD'S designed the study, collected and analysed the data, drafted and revised the manuscript, and approved the version to be published. SP and ER identified the patients, performed data collection, reviewed the manuscript and approved the version to be published. PR assisted with data analysis and interpretation, reviewed the manuscript, and approved and revised the version to be published.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.